de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Cushing's syndrome: drug targets and therapeutic options

MPG-Autoren

Paez-Pereda,  M
Max Planck Institute of Psychiatry, Max Planck Society;

Arzt,  E
Max Planck Institute of Psychiatry, Max Planck Society;

Stalla,  GK
Max Planck Institute of Psychiatry, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Paez-Pereda, M., Arzt, E., & Stalla, G. (2002). Cushing's syndrome: drug targets and therapeutic options. Expert Opinion on Therapeutic Patents, 12(10), 1537-1546.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-000E-A141-E
Zusammenfassung
Cushing''s syndrome is caused by endocrine and metabolic alterations produced by high levels of glucocorticoids. Glucocorticoid excess is usually a result of exogenous administration of glucocorticoids or alteration of the hypothalamus-pituitary-adrenal (HPA) axis. However, in the majority of patients it is due to an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma. Other possible causes are ectopic ACTH-secreting tumours of the lung, glucocorticoid-producing adrenal tumours and other ectopic tumours. The symptoms include central fat deposition, altered energy and protein metabolism, hypertension and depression. The molecular mechanisms that regulate the HPA axis provide a rationale to correct the alterations observed in Cushing''s syndrome. Recent developments have identified possible targets and drugs for therapy at different levels of the HPA axis. This article reviews patents claiming novel targets and drugs for Cushing''s syndrome in the period 1997-200